Relay Therapeutics rises after vascular disorder drug shows promise in study

Relay Therapeutics

19/05/2026 11:44

** Shares of drug developer Relay Therapeutics RLAY.O rise 11.3% to $13.37 premarket

** RLAY says its experimental treatment zovegalisib showed it can shrink vascular malformations and improve symptoms in patients with rare vascular disorders in a mid-stage study

** Zovegalisib reduced lesion size by at least 20% in about 60% of patients at 12 weeks

** Nearly all patients showed some reduction in lesion size and remained on treatment at the data cut-off, co says

** Vascular anomalies are rare conditions where blood or lymph vessels grow abnormally, leading to pain, swelling and other complications

** As of last close, RLAY was up 43% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))